Praxis Precision Medicines, Inc. (NASDAQ: PRAX) Q2 2025 Earnings | 08/04/2025
Praxis Precision Medicines, Inc. delivered a pivotal second quarter in 2025 marked by important clinical progress and intensified R&D investment, even as financial losses widened. The company recognized no revenue for the quarter—down from $0.4 million in Q2 2024—following the end of its collaboration with UCB. Research and development expenses more than doubled to $63.0 million (vs. $27.3 million in Q2 2024), primarily driven by increased activity in its Cerebrum™ and Solidus™ platforms and higher personnel costs. General and administrative expenses rose to $13.1 million, up from $10.6 millio…